Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update

References

• Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516–537. doi: 10.1016/j.jhep.2023.03.017
   PubMed Web of Science ®Google Scholar
• Fallowfield JA, Jimenez Ramos M, Robertson A. Emerging synthetic drugs for the treatment of liver cirrhosis. Expert Opin Emerg Drugs. 2021;26(2):149–163. doi: 10.1080/14728214.2021.1918099
   PubMed Web of Science ®Google Scholar
• Bentley TS, Ortner NJ. U.S. organ and tissue transplants: cost estimates, discussion, and emerging issues. Milliman Research Report. 2020 Jan. Available from: https://www.milliman.com/-/media/milliman/pdfs/articles/2020-us-organ-tissue-transplants.ashx
   Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475. doi: 10.1016/S0140-6736(12)61425-1
   PubMed Web of Science ®Google Scholar
• Friedman SL, Pinzani M. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology. 2022;75(2):473–488. doi: 10.1002/hep.32285
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Iredale JP, Fallowfield JA. Resolution of liver fibrosis: basic mechanisms and clinical relevance. Semin Liver Dis. 2015;35(2):119–131. doi: 10.1055/s-0035-1550057
   PubMed Web of Science ®Google Scholar
• Anstee QM, Neuschwander-Tetri BA, Wong V-S, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study. Clin Gastroenterol Hepatol. 2024;22(1):124–134.e1. doi: 10.1016/j.cgh.2023.04.003
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Sanyal AJ, Nakajima A, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. Clin Gastroenterol Hepatol. 2024;22(1):113–123.e9. doi: 10.1016/j.cgh.2023.04.012
   PubMed Web of Science ®Google Scholar
• Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511–522. doi: 10.1016/S2468-1253(23)00068-7
   PubMed Web of Science ®Google Scholar
• Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509. doi: 10.1056/NEJMoa2309000
   PubMed Web of Science ®Google Scholar
• Harrison SA, Neff GW, Lucas KJ, et al. Efruxifermin in compensated cirrhosis due to NASH/MASH: results from a randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY). Presented at the annual American Association for the Study of Liver Diseases (The Liver Meeting); 2023 Nov 10–14; Boston, United States. Hepatology; 2023;78( S1). p. S1–S2154.
   Google Scholar
• Rinella ME, Lieu HD, Kowdley KV, et al. A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024;79(3):674–689. doi: 10.1097/HEP.0000000000000607
   PubMed Web of Science ®Google Scholar
• Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158(5):1334–1345.e5. doi: 10.1053/j.gastro.2019.11.296
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Shevell DE, Tirucherai GS, et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2022;75(4):912–923. doi: 10.1002/hep.32181
   PubMed Web of Science ®Google Scholar
• Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547–1558. doi: 10.1056/NEJMoa2036205
   PubMed Web of Science ®Google Scholar
• Kimura K, Kanto T, Shimoda S, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine. 2022;80:104069. doi: 10.1016/j.ebiom.2022.104069
   PubMed Web of Science ®Google Scholar
• Mayo MJ, Vierling JM, Bowlus CL, et al. Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024;59(2):186–200. doi: 10.1111/apt.17755
   PubMed Web of Science ®Google Scholar
• Bruno BJ, Weavil JC, Ogle J, et al. Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in patients with cirrhosis. Presented at the annual American Association for the Study of Liver Diseases (The Liver Meeting); 2023 Nov 10–14; Boston, United States. Hepatology; 2023;78( S1). p. S1–S2154.
   Google Scholar
• Brennan PN, Elsharkawy AM, Kendall TJ, et al. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. Nat Rev Gastroenterol Hepatol. 2023;20(10):679–688. doi: 10.1038/s41575-023-00796-x
   PubMed Web of Science ®Google Scholar
• Kendall TJ, Jimenez-Ramos M, Turner F, et al. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2023;29(11):2939–2953. doi: 10.1038/s41591-023-02602-2
   PubMed Web of Science ®Google Scholar
• Nevens F, Gustot T, Laterre P-F, et al. A phase 2 study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. JHEP Rep. 2021;3(4):100291. doi: 10.1016/j.jhepr.2021.100291
   PubMedGoogle Scholar
• Brennan PN, Troland D, MacMillan M, et al. An open-label, parallel-group, phase 2 randomised controlled trial of autologous monocyte derived macrophage infusion in compensated cirrhosis. Presented at the annual American Association for the Study of Liver Diseases (The Liver Meeting); 2023 Nov 10–14; Boston, United States. Hepatology; 2023;78( S1). p. S1–S2154.
   Google Scholar